266 related articles for article (PubMed ID: 30014553)
1. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.
Lim YY; Hassenstab J; Goate A; Fagan AM; Benzinger TLS; Cruchaga C; McDade E; Chhatwal J; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield P; Morris JC; Maruff P; Bateman RJ;
Ann Neurol; 2018 Sep; 84(3):424-435. PubMed ID: 30014553
[TBL] [Abstract][Full Text] [Related]
2. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
[TBL] [Abstract][Full Text] [Related]
3. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
Lim YY; Hassenstab J; Cruchaga C; Goate A; Fagan AM; Benzinger TL; Maruff P; Snyder PJ; Masters CL; Allegri R; Chhatwal J; Farlow MR; Graff-Radford NR; Laske C; Levin J; McDade E; Ringman JM; Rossor M; Salloway S; Schofield PR; Holtzman DM; Morris JC; Bateman RJ;
Brain; 2016 Oct; 139(Pt 10):2766-2777. PubMed ID: 27521573
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
5. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.
Llibre-Guerra JJ; Li Y; Schindler SE; Gordon BA; Fagan AM; Morris JC; Benzinger TLS; Hassenstab J; Wang G; Allegri R; Berman SB; Chhatwal J; Farlow MR; Holtzman DM; Jucker M; Levin J; Noble JM; Salloway S; Schofield P; Karch C; Fox NC; Xiong C; Bateman RJ; McDade E
JAMA Netw Open; 2019 Dec; 2(12):e1917126. PubMed ID: 31825500
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
7. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
[TBL] [Abstract][Full Text] [Related]
8. The Influence of BDNF Val66Met Polymorphism on Cognition, Cerebrospinal Fluid, and Neuroimaging Markers in Non-Demented Elderly.
Xia H; Wang M; Li JQ; Tan CC; Cao XP; Tan L; Yu JT;
J Alzheimers Dis; 2019; 68(1):405-414. PubMed ID: 30775992
[TBL] [Abstract][Full Text] [Related]
9. Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease.
Horie K; Li Y; Barthélemy NR; Gordon B; Hassenstab J; Benzinger TLS; Fagan AM; Morris JC; Karch CM; Xiong C; Allegri R; Mendez PC; Ikeuchi T; Kasuga K; Noble J; Farlow M; Chhatwal J; Day G; Schofield PR; Masters CL; Levin J; Jucker M; Lee JH; Roh JH; Sato C; Sachdev P; Koyama A; Reyderman L; Bateman RJ; McDade E;
Ann Neurol; 2023 Jun; 93(6):1158-1172. PubMed ID: 36843330
[TBL] [Abstract][Full Text] [Related]
10. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
11. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
[TBL] [Abstract][Full Text] [Related]
14. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
15. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
16. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.
Li G; Peskind ER; Millard SP; Chi P; Sokal I; Yu CE; Bekris LM; Raskind MA; Galasko DR; Montine TJ
PLoS One; 2009; 4(5):e5424. PubMed ID: 19412541
[TBL] [Abstract][Full Text] [Related]
18. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.
Brown BM; Sohrabi HR; Taddei K; Gardener SL; Rainey-Smith SR; Peiffer JJ; Xiong C; Fagan AM; Benzinger T; Buckles V; Erickson KI; Clarnette R; Shah T; Masters CL; Weiner M; Cairns N; Rossor M; Graff-Radford NR; Salloway S; Vöglein J; Laske C; Noble J; Schofield PR; Bateman RJ; Morris JC; Martins RN;
Alzheimers Dement; 2017 Nov; 13(11):1197-1206. PubMed ID: 28501451
[TBL] [Abstract][Full Text] [Related]
19. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
